This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bereczki, D. Articles by Fekete, I. Search for Related Content PubMed PubMed Citation Articles by Bereczki, D. Articles by Fekete, I. Related Collections Acute Cerebral Hemorrhage Acute Cerebral Infarction Other Stroke Treatment - Medical

(Stroke. 2000;31:2719.)
© 2000 American Heart Association, Inc.

Comments, Opinions, and Reviews

Cochrane Report

A Systematic Review of Mannitol Therapy for Acute Ischemic Stroke and Cerebral Parenchymal Hemorrhage

Dániel Bereczki, MD, PhD; Ming Liu, MD; Gilmar Fernandes do Prado, MD, PhD István Fekete, MD, PhD

From the Department of Neurology, University of Debrecen, Medical School, Debrecen, Hungary (D.B., I.F.); Department of Neurology, First University Hospital, West China University of Medical Sciences, Chengdu, Sichuan, China (M.L.); and Department of Internal Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil (G.F.P.).

Background—Mannitol was reported to decrease cerebral edema associated with tissue damage and is used to treat acute stroke in many countries.

Summary of Review—We tested whether there is any evidence from unconfounded randomized clinical trials that treatment with mannitol reduces short- and long-term case fatality and dependency if administered after ischemic stroke or cerebral parenchymal hemorrhage. Trials were identified by the standard search strategy of the Cochrane Collaboration Stroke Review Group. A supplementary MEDLINE search was performed, and the Chinese Stroke Trials Register and the Latin-American databank LILACS were checked. A search was performed of master’s and PhD degree theses in the databank of Sao Paulo University and in abstracts of medical congresses on neurology and neurosurgery during 1965–1997 in Brazil. Investigators were contacted for unpublished information. Only truly randomized unconfounded clinical trials were eligible for inclusion. Two of the reviewers independently extracted data from the trials. Data synthesis and analysis was performed with the use of the Cochrane Review Manager software (RevMan version 4.0.4).

Conclusions—Only 1 trial fulfilled the inclusion criteria. The number of included patients was small, and the follow-up was short. Case fatality, the proportion of dependent patients, and side effects were not reported and were not available from the investigators. As a result of lack of appropriate randomized trials, currently no conclusion can be drawn on the effects of mannitol in acute stroke. The routine use of mannitol in all patients with acute stroke is not supported by evidence from randomized controlled clinical trials.

Key Words: mannitol • randomized controlled trials • stroke, acute • treatment outcome

This article has been cited by other articles:

				M. A. Koenig, M. Bryan, J. L. Lewin III, M. A. Mirski, R. G. Geocadin, and R. D. Stevens Reversal of transtentorial herniation with hypertonic saline Neurology, March 25, 2008; 70(13): 1023 - 1029. [Abstract] [Full Text] [PDF]

				D. Bereczki, L. Mihalka, S. Szatmari, K. Fekete, D. Di Cesar, B. Fulesdi, L. Csiba, and I. Fekete Mannitol Use in Acute Stroke: Case Fatality at 30 Days and 1 Year Stroke, July 1, 2003; 34(7): 1730 - 1735. [Abstract] [Full Text] [PDF]

				S. Schwarz, D. Georgiadis, A. Aschoff, and S. Schwab Effects of Hypertonic (10%) Saline in Patients With Raised Intracranial Pressure After Stroke Stroke, January 1, 2002; 33(1): 136 - 140. [Abstract] [Full Text] [PDF]

				L. Restrepo, I. E. Silverman, D. Bereczki, I. Fekete, M. Liu, and G. F. do Prado Osmotherapy: A Call to Arms Response Stroke, March 1, 2001; 32(3): 811 - 812. [Full Text] [PDF]